title: A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
abstract: BACKGROUND
  To evaluate the efficacy and safety of combination chemotherapy of cisplatin (5-day continuous infusion) and docetaxel for the treatment of previously untreated patients with advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Eligible patients had an ECOG performance status of 0-2 with measurable NSCLC. Patients received continuous infusion cisplatin 20 mg/m2/day on 5 days and bolus docetaxel 60 mg/m2/day (day 1; PiD therapy) at a 4-week interval.
  
  
  RESULTS
  Forty-three patients were enrolled. The mean number of cycles administered per patient was 2, and ranged from 1 to 4. The response rate was 49% (95% confidence interval, 33.9-63.8%). The median survival time was 47 weeks and the 1-year survival rate was 47%. The major toxic effects were grade 3 or 4, neutropenia (88%), leukopenia (81%), thrombocytopenia (14%) and anemia (42%). There were no treatment-related deaths.
  
  
  CONCLUSIONS
  PiD therapy was a well-tolerated and active regimen for patients with advanced NSCLC. The major toxicity was neutropenia.
authors.affiliation: Department of Thoracic Diseases, Tochigi Cancer Center, Yonan, Utsunomiya, Japan. kmori@tcc.pref.tochigi.jp
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Mori
authors.forename: Yukari
authors.initials: Y
authors.lastname: Kamiyama
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kondo
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Kano
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kodama
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin